Additionally, the binding of LAG-3 to the soluble liver-secreted Fibrinogen-Like protein 1 (FGL-1) has been shown to inhibit CD8+ T cell-mediated anti-tumor effects, but the significance of this interaction in hematologic malignancies remains to be elucidated (100). Here, LAG3 is linked to hematologic disorder.